Clinical Analysis of Intratympanic Injection of Dexamethasone for Treating Sudden Deafness
Xin Li,Wen-Jing Chen,Jia Xu,Hai-Jin Yi,Jing-Ying Ye
DOI: https://doi.org/10.2147/IJGM.S304123
IF: 2.145
2021-06-16
International Journal of General Medicine
Abstract:Xin Li, 1, 2 Wen-Jing Chen, 1, 2 Jia Xu, 1 Hai-Jin Yi, 1, 2 Jing-Ying Ye 1, 2 1 Department of Otorhinolaryngology, Beijing Tsinghua Changgung Hospital, Beijing, 102218, People's Republic of China; 2 School of Clinical Medicine, Tsinghua University, Beijing, 100084, People's Republic of China Correspondence: Hai-Jin Yi Department of Otorhinolaryngology, Beijing Tsinghua Changgung Hospital, No. 168, Litang Road, Changping District, Beijing, 102218, People's Republic of China Tel/Fax +86 10 56118899 Email Introduction: A variety of causes may induce sudden deafness. However, it remains challenging to determine the exact cause in a clinic. There is no standard treatment for this disease due to its unclear etiology. Objective: The present study aims to investigate the clinical efficacy of the intratympanic injection of dexamethasone for treating sudden deafness. Methods: A total of 154 patients with sudden deafness were retrospectively analyzed. The evaluation of sudden deafness was based on the AAO-HNS efficacy evaluative criteria. All patients were initially treated within seven days by an intravenous drip of methylprednisolone, vasodilator, and neurotrophic agents. These patients were divided into two groups: the treatment group (91 patients) and the control group (63 patients). Patients in the treatment group were given an intratympanic injection of dexamethasone, while patients in the control group were given conventional vasodilators and neurotrophic treatment. Results: The effective rate in the treatment group was 47.25% (43/91 patients), and this was significantly higher than in the control group (14.29%, 9/63 patients). The adverse reactions in the treatment group included transient pain (7.69%, 7/91), but there was no vertigo in either group. There was one case of tympanic membrane perforation. Conclusion: The intratympanic injection of dexamethasone is a better choice for refractory sudden deafness due to its high efficacy and fewer adverse reactions. Keywords: sudden deafness, dexamethasone, tympanic injection Sudden deafness refers to subjective feelings of hearing impairment that rapidly occur in one or both ears, which can be classified as conductive hearing loss, sensorineural hearing loss, or mixed hearing loss. 1 This may be induced by various causes, such as infection, tumors, tumor-like lesions, and round window membrane rupture. 2 A report evaluated the efficacy and safety of high-dose dexamethasone injection in the tympanic cavity in patients with sudden deafness who failed conventional treatment. 3 They found that high-dose dexamethasone injection into the tympanic cavity is more effective than conventional therapy after one week of treatment. At present, two theories have been widely recognized: viral infection and circulatory disorders of the inner ear. However, there is no standard treatment for this disease due to the unclear etiology. 4 Thus, the clinical use of antiviral drugs, steroids, vasodilators, neurotrophic agents, and other drugs is an important choice for patients with sudden deafness. Although the efficacy of systemic corticosteroid treatment for deafness has been confirmed, there are still apparent side effects, such as Cushing's syndrome, induced or aggravated infection, and depression. 5–7 In addition, the application of systemic steroids remains limited due to the blood–lymph barrier. 8 Hence, there is an urgent need to identify an agent that can exert better efficacy for sudden deafness with fewer side effects. At present, the intratympanic injection of steroids has been applied to sudden deafness as a remedy therapy, especially for the elderly. 9 Therefore, the efficacy of the intratympanic injection of dexamethasone was investigated in the present study, and its clinical efficacy was evaluated. A total of 154 patients with sudden deafness seen at the Department of Otorhinolaryngology Head and Neck Surgery, Tsinghua Changgung Hospital, from January 1, 2016, to December 30, 2020, were retrospectively analyzed. This study was conducted in accordance with the Declaration of Helsinki. The Ethics in Research Committee of Tsinghua Changgung Hospital approved the present study. All patients signed written informed consent. The sudden deafness was evaluated according to the criteria of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). 10 Patients diagnos -Abstract Truncated-
medicine, general & internal